SHILPAMED
OVERVALUEDShilpa Medicare Limited
Healthcare · NSE
↓ 516.5% vs fair value
52W Low
₹260
+86.7% from low
52W High
₹500
-3.1% from high
Valuation Gauge
Current Price
₹485
Fair Value
₹79
Fair Value Analysis
₹79
Based on balance sheet strength analysis and earnings growth potential for Healthcare sector companies | ROCE improving (latest 10.7%) — capital allocation becoming more efficient.
Balance Sheet Value
33% weight
Growth Valuation
67% weight
Price vs Market
Shareholding Pattern
Stock Health Score
Solid Fundamentals
Profitability
ROE of 6.2% is below the Healthcare sector benchmark of 15%
Debt & Leverage
D/E ratio of 0.2x is well within the Healthcare sector norm of 0.8x — strong balance sheet
Valuation vs Peers
P/E of 96.1x trades at a 40% discount to Healthcare sector median (160x) — attractively valued
Cash Flow
Negative FCF of ₹-111 Cr — company is consuming more cash than it generates
Earnings Growth
5yr EPS CAGR of 8.9% is well below Healthcare sector average of 18.7%
Dividend
Dividend yield of 0.1% is symbolic — low but positive
Company Health Timeline
10-year financial health at a glance
Sentiment Trend — Last 30 Days
Historical Returns
Key Ratios & Growth
FCF Yield
-0.7%
Free cash flow / market cap
Revenue Growth (YoY)
+28.5%
Year-on-year revenue change
Profit Growth (YoY)
+40.6%
Year-on-year PAT change
Operating Cash Flow
₹132 Cr
TTM cash from operations
Key Financials
EPS (TTM)
₹5
P/E Ratio
96.1x
P/B Ratio
3.9x
ROE
6.2%
ROCE
7.5%
Debt / Equity
0.24x
Beta
0.14
Div Yield
0.1%
FCF (Cr)
₹-111 Cr
Revenue (Cr)
₹1,285 Cr
EPS Growth 5Y
8.9%
Mkt Cap (Cr)
₹9,357 Cr
52W High
₹500
52W Low
₹259.5
Book Value/Share
₹123.5
Financial History
| Period | Revenue | Op Profit | OPM% | PAT | EPS |
|---|---|---|---|---|---|
| TTM | ₹1.4K Cr | ₹390 Cr | 27.0% | ₹150 Cr | ₹7.67 |
| 2025-03-31 | ₹1.3K Cr | ₹316 Cr | 25.0% | ₹78 Cr | ₹4.00 |
| 2024-03-31 | ₹1.1K Cr | ₹239 Cr | 21.0% | ₹32 Cr | ₹1.84 |
| 2023-03-31 | ₹1.0K Cr | ₹99 Cr | 9.0% | ₹-31 Cr | ₹-1.87 |
| 2022-03-31 | ₹1.1K Cr | ₹202 Cr | 18.0% | ₹61 Cr | ₹3.49 |
| 2021-03-31 | ₹899 Cr | ₹181 Cr | 20.0% | ₹146 Cr | ₹9.06 |
| 2020-03-31 | ₹908 Cr | ₹219 Cr | 24.0% | ₹155 Cr | ₹9.57 |
| 2019-03-31 | ₹733 Cr | ₹148 Cr | 20.0% | ₹110 Cr | ₹6.88 |
| 2018-03-31 | ₹789 Cr | ₹155 Cr | 20.0% | ₹103 Cr | ₹6.45 |
| 2017-03-31 | ₹779 Cr | ₹165 Cr | 21.0% | ₹104 Cr | ₹6.71 |
| 2016-03-31 | ₹719 Cr | ₹153 Cr | 21.0% | ₹99 Cr | ₹6.73 |
| 2015-03-31 | ₹614 Cr | ₹129 Cr | 21.0% | ₹73 Cr | ₹4.78 |
| 2014-03-31 | ₹571 Cr | ₹116 Cr | 20.0% | ₹75 Cr | ₹5.14 |
Compounded Growth Rates
Sales Growth
Profit Growth
EPS Growth
Peer Comparison
Healthcare| Stock | Price | Fair Value | MoS% | P/E | ROE | Signal |
|---|---|---|---|---|---|---|
Anlon Healthcare Limited | ₹13.9 | ₹50.7 | +72.6% | 20.5 | 7.3% | UNDERVALUED |
Alpa Laboratories Limited | ₹69.8 | ₹196.4 | +64.5% | 12.8 | 13.4% | FAIRLY_VALUED |
Aster DM Healthcare | ₹755.4 | ₹1,585.8 | +52.4% | 117.6 | 7.9% | UNDERVALUED |
Vimta Labs Limited | ₹453 | ₹722.6 | +37.3% | 26.2 | 18.6% | UNDERVALUED |
Unichem Laboratories Limited | ₹372.6 | ₹592.5 | +37.1% | 8.9 | 12.1% | FAIRLY_VALUED |
Dishman Carbogen Amcis Limited | ₹195.5 | ₹281.2 | +30.5% | 25.6 | 1.9% | FAIRLY_VALUED |
Indraprastha Medical Corporation Limited | ₹358.2 | ₹462.6 | +22.6% | 18.5 | 20.6% | UNDERVALUED |
Morepen Laboratories Limited | ₹43 | ₹52.8 | +18.5% | 23.3 | 10.8% | FAIRLY_VALUED |
Institutional Activity
Bulk deals, block deals, short selling & delivery volume — NSE data
Insider Trading
Community Pulse
Share this Stock
Download card · Share on WhatsApp
Share on WhatsApp, Twitter, or any group — each share brings new users to Veritas Quant